MAP2 and Alzheimer disease: These results indicate that MAP2 and GRIN1 are primarily expressed in excitatory neurons, but their reduction in the early stages of AD predominantly occurs in interneurons, potentially impairing interneuron function and leading to excessive neuronal hyperactivity, which contributes to AD progression.